Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue."

Doriana Landi^{1

2}, Diego Centonze^{1

2}, Girolama Alessandra Marfia^{1

2}, Ruggero Capra³, Cristina Scarpazza³

Affiliations

¹ Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
² IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Isernia, Italy.
³ Multiple Sclerosis Center, Spedali Civili di Brescia, Montichiari, Brescia, Italy.

Comment

Doriana Landi et al. J Clin Apher. 2018 Jun.

. 2018 Jun;33(3):450-451.

doi: 10.1002/jca.21616. Epub 2018 Feb 12.

Doriana Landi^{1

2}, Diego Centonze^{1

2}, Girolama Alessandra Marfia^{1

2}, Ruggero Capra³, Cristina Scarpazza³

¹ Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
² IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Isernia, Italy.
³ Multiple Sclerosis Center, Spedali Civili di Brescia, Montichiari, Brescia, Italy.

No abstract available

Comment on

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Schwartz J, et al. J Clin Apher. 2016 Jun;31(3):149-62. doi: 10.1002/jca.21470. J Clin Apher. 2016. PMID: 27322218